Seventeen patients with typical angina pectoris have been given alprenolol in a randomized double-blind cross-over trial. The drug was given twice daily in a total dosage of 200 mg/day, 400 mg/day, and 800 mg/day over 2-week periods, so that the total trial (excluding the run-in period) covered 3 months.
An increasing number of beta-adrenergic receptor blocking drugs are being introduced into clinical practice for the treatment of patients with angina pectoris with different *degrees of positive sympathomimetic action and of 'quinidine-like' action. We have shown elsewhere in studies of normal volunteers (J. Hoy and E. Sowton, I970, published data), in relatively normal subjects during exercise (Gibson, Hoy, and Sowton, 1970) , and in patients with angina pectoris (R. Balcon, I970, personal communication) or other cardiac diagnoses (J. Hoy and E. Sowton, 1970, unpublished data) 1 Present address: Guy's Hospital, London S.E.r. 12 present study we have attempted to assess the effectiveness of oral alprenolol (Aptin, Betap- tin, H56/28, I-(o-allylphenoxy)-3-isopropylamino-2-propanol) in the prophylactic treatment of patients with angina pectoris and also to obtain information concerning the dose levels likely to be most effective. This drug possesses some degree of positive sympathomimetic action and has a 'quinidine-like' effect in addition to its beta-adrenergic receptor blocking action (Ablad, Brogird, and Ek, 1967; Forsberg and Johnsson, I967) .
The importance of dose levels in treatment of angina pectoris is well recognized, and it is frequently suggested that during the run-in period of an angina trial the dose should be increased to the optimum level for each individual patient. In our view this prejudges the issue and tends to invalidate the trial, since it is obviously impossible to determine an optimum dose for a drug without assuming that it is effective. To avoid this complication we studied the patients in the present trial on 3 different dose levels -200 mg a day, 400 mg a day, and 800 mg a day.
Patients and methods
All patients were attending the outpatient department of the National Heart Hospital, London. Angina pectoris was diagnosed on the basis of a typical clinical story in association with ischaemic changes in the electrocardiogram; typical ST segment depression occurred during exercise in all cases. Patients with a normal resting cardiogram, heart failure, valve lesions, chronic respiratory disease, or arthritis limiting exercise on a bicycle ergometer, were excluded. The patients were studied during a stable phase of the disease with no significant alteration in severity of anginal pain over the past 3 months, and all patients were experiencing at least one attack of angina a day at the start of the trial. Three patients were receiving digoxin and five were on anticoagulants; these drugs were continued during the trial.
There were 17 men and 2 women with ages ranging from 37 tO 74 (mean age 55). Details of the patients studied are shown in Table i . All subjects were aware that the trial included new drugs in varying doses, and informed consent was obtained in all cases.
The effect of the drug was assessed in terms of the increase of the total work performed on a bicycle ergometer before pain, by the degree of ST segment depression during effort, and by the consumption of trinitrin tablets during the placebo and active periods. Exercise tests were performed in the erect position on a bicycle ergometer (Elema Schonander), with the exercise load being increased every 3 minutes until the patient was stopped by pain. Electrocardiograms were continuously recorded and used for subsequent calculations of heart rate at different exercise levels. The total work performed was calculated as the sum of the products of time and work load. This method of assessment has the advantage that the work performed increases slowly at the beginning but more rapidly as the test continues so that it is applicable to patients with all degrees of limitation (Fig. i) . The protocol for the exercise test was identical for an individual patient at all visits, but the work loads chosen were not necessarily the same for different patients since their total exercise tolerance differed. Resuscitation equipment including a defibrillator was immediately available throughout all exercise testing, but there were no complications associated with the exercise test during this study.
Many of the patients participating in this trial had previously taken part in a similar trial with practolol (Sowton et al., 197I) , and this acted as a very effective run-in period. Patients who joined the present trial without previously participating in a similar trial started with a one-month run-in period including exercise tests at the start, again at 2 weeks, and at 4 weeks.
On entering the trial patients were given a full examination including i2-lead electrocardiogram and chest x-ray, and their total exercise tolerance before pain was assessed with an exercise test. Blood was taken for measurements of haemoglobin, white cell count, urea, serum enzymes (GOT and GPT), cholesterol, and serum drug levels. In all, I9 patients completed the full 3-month trial but occasional patients were unable to attend for every fortnightly exercise test owing to social or employment commitments. Under these circumstances the patients were asked to continue taking the tablets (sent by post) in the ordinary way so as to preserve the continuity of their treatment. The analysis of exercise tolerance was restricted to those patients in whom full data had been obtained at the exercise tests, immediately before, during, and at the end of each period. This resulted in data being available on I7 patients during the 200 mg a day period, 14 patients during the 400 mg a day period, and I8 patients during the 800 mg a day period. The results of each of these dose levels may be regarded as separate assessments since the patient population studied was not completely identical but the very large degree of overlap allows cautious conclusions to be drawn concerning the effectiveness of the different doses.
Statistical significance was analysed by the Student 't' test.
Results
Exercise tolerance While on 200 mg a day there was an increase of 2I per cent in total work performed before angina by the group during the alprenolol period, in excess of that during the placebo period. This difference is statistically significant (P < 0.02). During the month when the patients were taking 400 mg 'a day the total work after 2 weeks on active tablets was I7 per cent more than that after the placebo treatment. This increase was also statistically significant (P < o os). There was also an increase in total work (14%) after the fortnight on alprenolol during the 800 mg a day period, but this was not statistically Vsignificant.
Heart rate Heart rate was reduced after the period of active tablets compared with placebo, both at rest and on effort at all three dose levels. The reduction with 200 mg a day was not statistically significant, but on 400 Tables 2 and 3 which present the mean results for all patients of heart rate on effort, systolic blood pressure, and total work before pain.
Patient's preference On the 200 mg a day dose only 2 patients preferred the active tablets, 7 preferred the placebo, and 8 had no preference. On the 400 mg a day dose, 4 patients preferred the active compound, i the placebo, and 9 had no preference. However, on the 800 mg a day dose there were io patients who preferred the active tablets, 4 the placebo, and 4 had no preference. These differences are not statistically significant.
ST segment change The effect of alprenolol on the degree of ST segment depression during exercise is shown in Table 4 . ST segments were less depressed after the period of active tablets compared with placebo both at comparable work loads and at the onset of angina (Fig. 2) Table 5 ), so that the exercise tolerance we have measured at the end of a fortnight of placebo treatment is unlikely to be influenced by the preceding period on active tablets. The mean levels for all available results are 23-5 ng/g, with a dose of I00 mg twice a day (n = 6), 66 ng/g with a dose of 200 mg twice a day (n = 7), and 74 ng/g with a dose of 400 mg twice a day (n = 9).
Discussion
The results of our trial show that alprenolol is an effective agent in the prophylaxis of angina pectoris and that statistically significant increases in effort tolerance are produced by oral doses of 200 mg a day and 400 mg a day. This is in agreement with Arstila, Iisalo, and Kallio (I969) who found significant increases in exercise tolerance with a dose of 225 mg a day. The improvement in exercise tolerance is unlikely to be related entirely to the changes in heart rate since the high dose group (800 mg a day) had a statistically significant reduction in rate but no improvement in work tolerance, whereas the low dose group (200 mg a day) had statistical improvement in effort tolerance but no statistical change in heart rate. Our results are in keeping with those of Bjorntorp (I968) who carried out doubleblind trials with oral alprenolol in a dosage of 100 mg 4 times a day, and showed that the frequency of anginal attacks was statistically significantly reduced.
The same dose was used in a multicentre trial in Australia reported by Hickie (I970) in which the frequency of anginal attacks was reduced 40 per cent by placebo treatment and 69 per cent by alprenolol. H. Ikram (1970, personal communication) also chose a dose of I00 mg 4 times daily and reported a significant reduction in frequency of attacks during the treatment periods, but our data do not confirm his suggestion that a greater therapeutic effect would be expected from higher doses. Aubert et al. (I970) were able to show in Norway that 400 mg a day of alprenolol produced important clinical improvement in two-thirds of 2I patients, but Wasserman et al. (1970) failed to show an antianginal effect from I00 mg alprenolol given 4 times a day, to 9 patients.
In another trial using a small dose, 75 mg 3 times a day, Arstila et al. (I969) concluded that the dose was probably inadequate since they noticed a larger fall in nitroglycerin consumption than in the frequency of attacks, but There is no clear definition by which a patient can be said to have improved while taking an antianginal drug. While one patient may have fewer attacks of angina in the week, another patient may utilize the increased effort tolerance to perform more exercise and still experience the same number or even more attacks of angina. A further possibility is that the frequency of attacks remains constant but that their character changes so that the pain is less severe. This information must relate to the period when the patient is out of hospital living his ordinary life and so can only be obtained by questioning him at his next attendance. Though we made an attempt to assess patients' preference between placebo and active periods, we were unable to draw satisfactory conclusions. A similar attempt was made by Aubert et al. (I970) in their study of alprenolol (400 mg a day), pentaerythritol tetranitrate (30 mg four times a day), and placebo in patients with angina pectoris. They were unable to determine any difference in severity in attacks between pentaerythritol tetranitrate and placebo tablets, and concluded that the means available to evaluate the point were inadequate, though they reported a reduction in the severity of attacks with alprenolol.
The device of issuing a known number of nitroglycerin tablets at each visit and counting those remaining at the next visit in order to assess the number of anginal attacks is widely used, but it assumes that the patients will take nitroglycerin tablets in exactly the same way during placebo and active periods of treatment and also that they will not use the tablets prophylactically. The instruction to a patient not to use the tablets prophylactically contravenes standard clinical practice and is almost certainly the exact opposite of advice given throughout his previous medical treatment. Though the practice may be justified ethically, there is no doubt that many patients are confused by the conflict of advice and in this study close questioning revealed that several patients had taken their tablets prophylactically on at least a few occasions. This may account for the failure of the nitroglycerin consumption figures to drop statistically. We have experienced similar difficulties with tablet counts in other double-blind crossover trials of antianginal agents (Sowton et al., 197i) , and we no longer feel that this method of assessment is satisfactory.
Our results show an increased effort tolerance with doses of Ioo mg and 200 mg twice a day but not 400 mg twice a day. This difference is unlikely to be due to inadequate absorption since Johansson (i969) showed alprenolol to be completely absorbed and the mean serum levels in these two groups in the present study were higher for the 800 mg a day group than for the 400 mg a day group. Alternatively it might be due to an exercise depression of cardiac function by the large doses of alprenolol or possibly to peripheral effects limiting the total amount of exercise possible. There were no clinical findings to support the view that cardiac output was unduly depressed with a large dose, and if this were the explanation it would then be expected that the systolic blood pressure of these patients was lower and that they achieved a total work less than that achieved on lower doses. The actual figures illustrated in Table 3 show that it is unlikely that the high level group were experiencing undue depression of cardiac function. The failure of high doses to improve exercise tolerance may therefore be due to a minor degree of generalized muscle weakness such as is produced by high doses of most other beta-adrenergic blocking drugs.
The improvement in effort tolerance obtained by our patients was appreciable and was associated with electrocardiographic evidence suggesting less cardiac ischaemia at all exercise levels. We do not feel this evidence is negated by our failure to show a reduction in nitroglycerin consumption, and we conclude that alprenolol is an effective drug for the prophylactic treatment of patients with angina pectoris.
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